Publications by authors named "Robert D Little"

The pathogenesis of inflammatory bowel disease (IBD) is complex and multifactorial. Undertreated disease has substantial individual and societal consequences. Current patient classification and subsequent positioning of IBD therapy are based on crude, readily accessible clinical data.

View Article and Find Full Text PDF

Background: Few studies have explored the relationship between habitual dietary patterns and disease activity in people with Inflammatory Bowel Disease (IBD). This cross-sectional study explored the association between dietary patterns and clinical and objective markers of inflammation in adults from the Australian IBD Microbiome Study.

Methods: Dietary patterns were derived using principal component analysis (PCA) of baseline food frequency questionnaire data.

View Article and Find Full Text PDF
Article Synopsis
  • Therapeutic Drug Monitoring (TDM) is crucial for managing inflammatory bowel disease (IBD) patients on infliximab (IFX) or adalimumab, especially when there's a loss of response to these treatments; however, TDM isn't recommended for other biologic therapies.
  • A review of literature indicates that TDM might be beneficial for IFX subcutaneous (SC) use, while it's not effective for golimumab, and findings on vedolizumab are inconsistent; ustekinumab shows some promise, but less so than anti-TNF agents.
  • Recent advancements suggest that using dashboard systems for precision dosing of anti-TNF agents could optimize treatment, emphasizing a proactive approach to TDM.
View Article and Find Full Text PDF

Introduction: A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional intravenous infliximab is labour-intensive and expensive, depending on insurance and pharmaceutical reimbursement. Observational data suggest that subcutaneous infliximab may offer a convenient and safe alternative to maintain disease remission in patients requiring dose-intensified infliximab.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the relationship between adalimumab (ADA) drug levels and Crohn's disease (CD) activity in patients who experienced a loss of response and underwent dose intensification.
  • It analyzed a group of 131 CD patients over five years, measuring ADA levels at critical points after the dose increase and assessing the impact on clinical and objective remission.
  • Findings indicate that higher ADA levels monitored at 6 and 12 months after dose-intensification are linked to improved remission rates, suggesting that post-treatment monitoring is more informative than initial baseline levels.
View Article and Find Full Text PDF
Article Synopsis
  • Concomitant immunomodulation is used with anti-TNF therapy for Inflammatory Bowel Disease (IBD) to boost drug levels and reduce the formation of anti-drug antibodies.
  • Thiopurines have been the go-to immunomodulators, but concerns over long-term safety and potential links to lymphoproliferative disorders have emerged.
  • Research indicates that low-dose oral methotrexate may be a safer alternative, improving the effectiveness of anti-TNF agents and showing similar efficacy and better tolerance compared to higher-dose injections.
View Article and Find Full Text PDF

Objective: Idiopathic megarectum is characterized by abnormal, pronounced rectal dilatation in the absence of identifiable organic pathology. Idiopathic megarectum is uncommon and under-recognized. This study aims to describe the clinical features and management of idiopathic megarectum.

View Article and Find Full Text PDF

CT-P13 is the first subcutaneous infliximab molecule approved for the management of inflammatory bowel disease (IBD). Compared to intravenous therapy, SC infliximab offers a range of practical, micro- and macroeconomic advantages. Data from the rheumatological literature suggest that subcutaneous CT-P13 may lead to superior disease outcomes in comparison to intravenous infliximab.

View Article and Find Full Text PDF

Purpose Of Review: Headache disorders in children and adolescents are common. Among the different headache disorders, migraine and tension headache are highly prevalent and often debilitating. Pharmacological treatments for pediatric patients are often not approved or effective.

View Article and Find Full Text PDF
Article Synopsis
  • A study assessed the outcomes of reducing anti-TNF therapy in patients with inflammatory bowel disease (IBD) who had achieved deep remission, finding that 64% maintained reduced dosing after 12 months.
  • The research involved monitoring patient demographics, disease characteristics, and biomarkers, with 'success' classified as remaining on lower doses while 'failures' required re-escalation or other interventions.
  • Results indicated that all patients who needed re-escalation responded well, suggesting that cautious de-escalation could be a viable option for patients in sustained remission on intensified therapy.
View Article and Find Full Text PDF

Background: Histological and epidemiological data suggest that increased signal intensity at the proximal patellar tendon on magnetic resonance imaging is a response to tendon loading. As patellofemoral geometry is a mediator of loading, we examined the association between patellofemoral geometry and the prevalence of increased signal intensity at the patellar tendon in community-based middle-aged adults.

Methods: Two hundred-one adults aged 25-60 years in a study of obesity and musculoskeletal health had the patellar tendon assessed from magnetic resonance imaging.

View Article and Find Full Text PDF

Background: Virtual clinics represent a novel model of care in inflammatory bowel disease. Their effectiveness in promoting high quality use of biologic therapy and facilitating a treat-to-target approach is unknown.

Aim: To evaluate clinical and process-driven outcomes in a virtual clinic compared to standard outpatient care amongst patients receiving intensified anti-TNF therapy for secondary loss of response.

View Article and Find Full Text PDF

Background: Adalimumab is administered via a pre-filled syringe or spring-loaded pen. In a previous study in Crohn's disease, higher drug levels were observed in syringe users. The aim of this study was to evaluate the impact of delivery device on adalimumab drug levels in patients with Crohn's disease.

View Article and Find Full Text PDF

Objective:: To question the status of the randomised controlled trial (RCT) in the hierarchy of evidence.

Conclusions:: The RCT provides important and clinically relevant information, particularly in psychopharmacology. However, and as with other methodologies, RCTs too are flawed and automatic abdication to their conclusions, especially in complex social interventions, is unwise.

View Article and Find Full Text PDF

Inflammatory activity in rheumatoid arthritis may alter the regulation of muscle mass leading to a secondary sarcopenia, commonly termed rheumatoid cachexia (RC). We characterized alterations to muscle structure and various pro-inflammatory, catabolic and regenerative markers in an animal model of RC. Antigen induced arthritis (AiA) was performed in 20 male adult rabbits.

View Article and Find Full Text PDF

Introduction: Subchondral bone mineral density (sBMD) contributes to the initiation and progression of knee osteoarthritis (OA). Reliable methods to assess sBMD status may predict the response of specific OA phenotypes to targeted therapies. While dual-energy X-ray absorptiometry (DXA) of the knee can determine sBMD, no consensus exists regarding its methodology.

View Article and Find Full Text PDF